Protalix BioTherapeutics Announces Presentation of Phase II Clinical Trial Results for alidornase alfa in Cystic Fibrosis at the 40th European Cystic Fibrosis Society Conference

CARMIEL, Israel, May 23, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE:PLX), announced today that an oral presentation highlighting the results from the Company’s phase II clinical trial of alidornase alfa (PRX-110) for the treatment of Cystic Fibrosis (CF) and including new clinical data will be given at the 40th European Cystic Fibrosis Society Conference which is being held June 7-10, 2017 in Seville, Spain. The oral presentation, titled “Phase II clinical tria... 

Protalix BioTherapeutics Reports 2017 First Quarter Results and Provides Corporate Update

Positive Results from Phase II Trial in CF Program with Number of Potential Strategic Alternatives for Further Development First Ever Once Monthly Dosing Trial in Fabry Patients to Commence Next Quarter Continued Progress in the Commercialization of alfataliglicerase in Brazil CARMIEL, Israel, May 10, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic prote... 

Protalix Announces FDA Investigational New Drug Clearance to Commence Once-Monthly Dosing Study of pegunigalsidase alfa (PRX-102) for the Treatment of Fabry Disease

Once Monthly Dosing Would Represent a 50% Reduction in Patient Infusions Unique Chemical Modifications to pegunigalsidase alfa Result in a Significantly Longer Half-life Allowing for the Potential of Effective Drug Coverage for Four Weeks Study Planned to Commence in the Third Quarter of 2017 CARMIEL, Israel, May 09, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the U.S. Food and Drug Administration (FDA) cleared an Investigation... 
All News